Silence Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.24	Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting (Businesswire)
14.11.24	Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Businesswire)
27.08.24	Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences (Businesswire)
15.08.24	Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Businesswire)
27.06.24	Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients (Businesswire)
24.06.24	Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration (Businesswire)
20.06.24	Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) (Businesswire)
30.05.24	Silence Therapeutics to Present at Jefferies Global Healthcare Conference (Businesswire)
16.05.24	Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress (Businesswire)
30.04.24	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference (Businesswire)
29.04.24	Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors (Businesswire)
08.04.24	Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) (Businesswire)
13.03.24	Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (Businesswire)
13.03.24	Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) (Businesswire)
28.02.24	Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024 (Businesswire)
23.02.24	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial (Businesswire)
05.02.24	Silence Therapeutics Announces Oversubscribed $120 Million Private Placement (Businesswire)
31.01.24	Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Businesswire)
01.12.23	Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments (Businesswire)
14.11.23	Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (Businesswire)
08.11.23	Silence Therapeutics to Present at Jefferies London Healthcare Conference (Businesswire)
01.11.23	Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease (Businesswire)
06.09.23	Silence Therapeutics to Participate in September Investor Conferences (Businesswire)
16.08.23	Silence Therapeutics Reports Second Quarter 2023 Results (Businesswire)
31.05.23	Silence Therapeutics to Present at the Jefferies Healthcare Conference (Businesswire)
16.05.23	Silence Therapeutics Reports First Quarter 2023 Results (Businesswire)
04.05.23	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration (Businesswire)
01.05.23	Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events (Businesswire)
25.04.23	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference (Businesswire)
04.04.23	Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera (Businesswire)
29.03.23	Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days (Businesswire)
28.03.23	Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development (Businesswire)
28.03.23	Silence Therapeutics to Buyback siRNA Complement Assets (Businesswire)
15.03.23	Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results (Businesswire)
02.03.23	Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023 (Businesswire)
08.02.23	Silence Therapeutics to Present at SVB Securities Global Biopharma Conference (Businesswire)
06.02.23	Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer (Businesswire)
12.01.23	Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates (Businesswire)
03.01.23	Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
10.11.22	Silence Therapeutics Reports Third Quarter 2022 Results (Businesswire)
09.11.22	Silence Therapeutics to Present at Jefferies London Healthcare Conference (Businesswire)
05.11.22	Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting (Businesswire)
29.09.22	Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia (Businesswire)
27.09.22	Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference (Businesswire)
08.09.22	Silence Therapeutics to Participate in September Investment Conferences (Businesswire)
08.09.22	Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera (Businesswire)
12.08.22	Silence Therapeutics Announces Pricing of Underwritten Offering (Businesswire)
02.06.22	Silence Therapeutics to Present at Jefferies Healthcare Conference (Businesswire)
18.05.22	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference (Businesswire)
16.05.22	Silence Therapeutics Reports First Quarter 2022 Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Silence Therapeutics PLC

Aktien Top/Flop

Meistgelesene Nachrichten